Drug Approval | December 18, 2023
Zydus receives final approval from the USFDA for Lacosamide Tablets
Lacosamide is indicated to treat partial-onset seizures
Lacosamide is indicated to treat partial-onset seizures
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
The Product will be manufactured at the company's facility in Bengaluru
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Subscribe To Our Newsletter & Stay Updated
